Profibrinolytic effect of Enzamin, an extract of metabolic products from Bacillus subtilis AK and Lactobacillus.
Fibrinolytic system impairment contributes to the development of thrombotic disease such as cardiovascular disease and stroke. Therefore, an agent that increases fibrinolytic activity may be useful for the prevention of these diseases. In this study, to explore novel profibrinolytic agents, we examined the profibrinolytic effect of Enzamin, an extract of metabolic products from Bacillus subtilis AK and Lactobacillus in vitro and in vivo. Enzamin directly enhanced plasmin activity generated by tissue-type plasminogen activator (t-PA) by twofold but not by urokinase-type plasminogen activator (u-PA) in vitro, which was measured employing both the chromogenic substrate H-D: -Val-Leu-Lys-pNA (S-2251) and fibrin plate. Enzamin also increased plasmin activity generated by t-PA in the cell lysate and culture medium of endothelial cells, measured by fibrin zymography. Furthermore, the oral administration of a 1% concentration of Enzamin increased plasmin activity generated by t-PA by 1.7-fold but not by u-PA in the euglobulin fraction of mouse plasma. In conclusion, Enzamin has a unique ability to enhance the fibrinolytic activity through an increase in endogenous plasmin activity generated by t-PA released from endothelial cells, and may be a beneficial supplement for the prevention of thrombotic episodes.
Department of Physiology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osakasayama, Osaka 589-8511, Japan.
Yukinori
Y
Tamura
Kiyotaka
K
Okada
Naoyuki
N
Kawao
Masato
M
Yano
Shigeru
S
Ueshima
Nobuo
N
Nagai
Osamu
O
Matsuo
D000818:Animals; D001412:Bacillus subtilis / Q000737:chemistry*; D001780:Blood Coagulation Tests; D002460:Cell Line; D045424:Complex Mixtures / Q000737:chemistry / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D005341:Fibrinolysin / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D005343:Fibrinolytic Agents / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology*; D007778:Lactobacillus / Q000737:chemistry*; D051379:Mice; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy; D010959:Tissue Plasminogen Activator / Q000097:blood
D045424:Complex Mixtures; D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin
Trends Neurosci. 2009 Jan;32(1):48-55
18963068
J Intern Med. 1991 Apr;229(4):309-16
1902868
Circulation. 2000 Jan 25;101(3):264-9
10645922
Thromb Res. 2003 Mar 15;109(5-6):233-40
12818244
Int J Obes Relat Metab Disord. 2004 Nov;28(11):1357-64
15356668
Blood. 2005 Feb 1;105(3):1102-5
15466929
Am J Hematol. 1996 Nov;53(3):151-7
8895684
J Am Coll Cardiol. 2010 May 11;55(19):2107-15
20447533
Appl Microbiol Biotechnol. 2005 Nov;69(2):126-32
16211381
Chem Pharm Bull (Tokyo). 1994 Sep;42(9):1854-8
7954938
Blood. 1991 Dec 15;78(12):3114-24
1742478
Thromb Haemost. 1995 Jul;74(1):167-71
8578451
N Engl J Med. 1995 Dec 14;333(24):1581-7
7477192
Blood. 1998 Jan 15;91(2):529-37
9427706
Haemostasis. 1986;16(1):43-50
3699585
Thromb Haemost. 2002 Jun;87(6):1069-74
12083488
J Thromb Haemost. 2006 Nov;4(11):2478-85
16970803
Thromb Haemost. 1990 Feb 19;63(1):82-6
2111051